Theravance Biopharma Now Expects FY24 Levels Of Both Non-GAAP Losses And Cash Burn To Be Similar To First Half Actuals 2024
Portfolio Pulse from Benzinga Newsdesk
Theravance Biopharma (TBPH) expects its FY24 non-GAAP losses and cash burn to be similar to the first half of 2024. The company projects full-year R&D expenses of $30 million to $36 million and SG&A expenses of $45 million to $55 million, excluding share-based compensation. Share-based compensation expenses are expected to be $18 million to $22 million.
August 05, 2024 | 8:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Theravance Biopharma expects its FY24 non-GAAP losses and cash burn to be similar to the first half of 2024. The company projects full-year R&D expenses of $30 million to $36 million and SG&A expenses of $45 million to $55 million, excluding share-based compensation. Share-based compensation expenses are expected to be $18 million to $22 million.
The news provides a detailed financial outlook for Theravance Biopharma, indicating stability in non-GAAP losses and cash burn. This could be seen as neutral by investors as it suggests no significant change in financial performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100